<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K/A
AMENDMENT NO. 4
/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1995
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO .
COMMISSION FILE NUMBER 0-23272
NPS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
<TABLE>
<S> <C>
DELAWARE 87-0439579
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification
No.)
420 CHIPETA WAY, SALT LAKE CITY, 84108-1256
UTAH
(Address of principal executive (Zip Code)
offices)
</TABLE>
(801) 583-4939
(Registrant's telephone number, including area code)
Securities registered under Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.001
Par Value
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for at least the past 90 days. YES /X/ NO / /
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. /X/ To the best of the Company's knowledge, there have been no
delinquent filers.
The approximate aggregate market value of the Common Stock held by
nonaffiliates of the Registrant was $47,898,779 as of March 31, 1996, based upon
the closing price of $12.75 for the shares of the Company's Common Stock
reported on The Nasdaq Stock Market.(1)
The number of shares of Common Stock outstanding as of March 31, 1996 was
8,187,232.
DOCUMENTS INCORPORATED BY REFERENCE: None
- ------------------------
(1) Excludes 4,430,465 shares of Common Stock held by directors, officers and
other affiliates as of March 31, 1996.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
REGISTRANT HEREBY AMENDS ITEM 14, EXHIBITS, FINANCIAL STATEMENT SCHEDULES,
AND REPORTS ON FORM 8-K AS FOLLOWS:
ITEM 14 EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(a) 1. INDEX TO FINANCIAL STATEMENTS AND REPORTS OF INDEPENDENT AUDITORS.
The Financial Statements required by this item are submitted in a separate
section beginning on page F-1 of this report.
<TABLE>
<CAPTION>
PAGE
NUMBER
-----------
<S> <C>
Index to Financial Statements........................................................................... F-1
Report of KPMG Peat Marwick LLP, Certified Auditors..................................................... F-2
Balance Sheets at December 31, 1995 and 1994............................................................ F-3
Statements of Operations for three years ended December 31, 1995, and for the period from inception to
December 31, 1995...................................................................................... F-4
Statements of Stockholders' Equity from inception through December 31, 1995............................. F-5
Statements of Cash Flows for the three years ended December 31, 1995, and from inception to December 31,
1995................................................................................................... F-8
Notes to Financial Statements........................................................................... F-10
</TABLE>
2. INDEX TO FINANCIAL STATEMENTS SCHEDULES. There are no Financial
Statements Schedules included because they are either not applicable or the
required information is shown in the Financial Statements or the notes thereto.
(b) The Registrant filed no reports on Form 8-K during the last quarter of
the fiscal year ended December 31, 1995.
3. EXHIBITS.
<TABLE>
<CAPTION>
EXHIBIT
NUMBER
- --------------
<S> <C>
3.1** Amended and Restated Certificate of Incorporation of the Registrant.
3.2** Amended and Restated Bylaws of the Registrant.
10.1** Stock Purchase Agreement between the Registrant and S.R. One, Limited, dated November 18, 1993.
10.2** Amended Agreement and Waiver, among the Registrant and the other parties thereto, dated November
18, 1993.
10.3** Form of Registrant's 1994 Non-Employee Directors' Stock Option Plan.
10.4** Form of Registrant's 1994 Equity Incentive Plan and Form of Stock Option Agreements.
10.5** Registrant's 1987 Stock Option Plan, as amended, and Form of Stock Option Agreement.
10.6** Form of Registrant's 1994 Employee Stock Purchase Plan and Form of Offering Document.
10.7** Master Lease Agreement between the Registrant and LINC Scientific Leasing, dated October 7,1992,
with related addenda.
10.8** Form of Indemnity Agreement entered into between the Registrant and its officers and directors.
10.9+** Collaborative Research and License Agreement between the Registrant and SmithKline Beecham
Corporation, dated November 1, 1993.
10.10+** Patent Agreement Between the Registrant and The Brigham and Women's Hospital, Inc., dated February
19, 1993, with related amendment.
10.11+** Research Agreement between the Registrant and The Brigham and Women's Hospital, Inc., dated
February 19, 1993, with related amendment.
10.15+**** Collaborative Research and License Agreement between the Registrant and Kirin Brewery Company,
Ltd. dated June 29, 1995.
</TABLE>
<PAGE>
<TABLE>
<S> <C>
10.16+ Development and License Agreement between the Registrant and Amgen Inc. effective as of December
27, 1995.
10.17+ Stock Purchase Agreement between Registrant and Amgen Inc. dated March 18, 1996.
10.18 Lease Agreement with GATX dated June 1, 1995, with related addenda.
10.19 Office Lease between Salt Lake Research Park Associates and Registrant dated June 3, 1994, with
related amendments.
10.20** Consultant Services Agreement between the Registrant and Thomas N. Parks, Ph.D., dated January 30,
1989.
10.21*** Consulting Agreement between the Registrant and Plexus Ventures, Inc. dated August 5, 1994, as
amended.
10.22+***** Binding Letter of Intent between Amgen Inc. and the Registrant dated December 27, 1995.
10.23+ Amendment effective February 7, 1996 to Research Agreement between the Registrant and The Brigham
and Women's Hospital, Inc. dated February 19, 1993.
10.24+ Amendment effective February 7, 1996 to Patent Agreement between the Registrant and The Brigham
and Women's Hospital, Inc., dated February 19, 1993.
10.25+ Amendment effective June 29, 1995 to the Collaborative Research and License Agreement between the
Registrant and SmithKline Beecham Corporation, dated November 1, 1993.
11.1* Statement regarding calculation of net loss per share.
23.1* Consent of KPMG Peat Marwick LLP, independent auditors.
</TABLE>
- ------------------------
* Previously filed with this Form 10-K for the fiscal year ended December
31, 1995.
** Incorporated herein by reference to the Registrant's registration
statement on Form S-1 filed January 21, 1994 (File No. 33-74318).
*** Incorporated herein by reference to the Registrant's Form 10-K for the
fiscal year ended December 31, 1994.
**** Incorporated herein by reference to the Registrant's Form 10-K for the
fiscal year ended December 31, 1994.
***** Incorporated herein by reference to the Registrant's Form 8-K dated
February 29, 1996.
+ Confidential treatment has been granted with respect to these exhibits.
(c) See Exhibits listed under Item 14(a)(3).
(d) The financial statement schedules required by this Item are listed
under Item 14(a)(2).
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities 13 or 15(d) of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report on Form
10-K to be signed on its behalf by the undersigned, thereunto duly authorized on
the 28th day of June, 1996.
NPS PHARMACEUTICALS, INC.
By /s/ JAMES U. JENSEN
-----------------------------------
James U. Jensen
VICE PRESIDENT, CORPORATE
DEVELOPMENT
AND LEGAL AFFAIRS
<PAGE>
INDEX TO FINANCIAL STATEMENTS
<TABLE>
<S> <C>
Report of KPMG Peat Marwick LLP, Independent Auditors................................ F-2
Balance Sheets....................................................................... F-3
Statements of Operations............................................................. F-4
Statements of Stockholders' Equity................................................... F-5
Statements of Cash Flows............................................................. F-8
Notes to Financial Statements........................................................ F-10
</TABLE>
F-1
<PAGE>
INDEPENDENT AUDITORS' REPORT
The Board of Directors
NPS Pharmaceuticals, Inc.:
We have audited the accompanying balance sheets of NPS Pharmaceuticals, Inc.
(a development stage company) as of December 31, 1994 and 1995, and the related
statements of operations, stockholders' equity, and cash flows for each of the
years in the three-year period ended December 31, 1995, and for the period from
October 22, 1986 (inception) through December 31, 1995. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of NPS Pharmaceuticals, Inc. (a
development stage company) as of December 31, 1994 and 1995, and the results of
its operations and its cash flows for each of the years in the three-year period
ended December 31, 1995, and for the period from October 22, 1986 (inception)
through December 31, 1995, in conformity with generally accepted accounting
principles.
KPMG PEAT MARWICK LLP
Salt Lake City, Utah
February 7, 1996, except as to note 11
which is as of March 18, 1996
F-2
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
ASSETS
<TABLE>
<CAPTION>
PRO FORMA
DECEMBER 31, (NOTE 11)
------------------------------ DECEMBER 31,
1994 1995 1995
-------------- -------------- --------------
<S> <C> <C> <C>
Current assets:
Cash and cash equivalents...................................... $ 5,931,082 $ 8,039,625 $ 25,539,625
Marketable investment securities (note 2)...................... 3,392,135 300,000 300,000
Accounts receivable............................................ 260,000 23,000 23,000
-------------- -------------- --------------
Total current assets......................................... 9,583,217 8,362,625 25,862,625
-------------- -------------- --------------
Plant and equipment (note 4):
Equipment...................................................... 2,039,441 2,272,006 2,272,006
Leasehold improvements......................................... 1,603,424 1,635,189 1,635,189
-------------- -------------- --------------
3,642,865 3,907,195 3,907,195
Less accumulated depreciation and amortization................. 1,209,298 1,711,551 1,711,551
-------------- -------------- --------------
Net plant and equipment...................................... 2,433,567 2,195,644 2,195,644
Other assets, at cost............................................ 67,028 42,154 42,154
-------------- -------------- --------------
$ 12,083,812 $ 10,600,423 $ 28,100,423
-------------- -------------- --------------
-------------- -------------- --------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current installments of obligation under capital leases (note
4)............................................................ $ 413,001 $ 435,230 $ 435,230
Current installments on long-term debt (note 5)................ -- 331,746 331,746
Accounts payable............................................... 924,480 1,036,464 1,036,464
Accrued expenses............................................... 141,511 139,714 139,714
Deferred income................................................ -- 587,500 587,500
Income tax payable (note 7).................................... -- -- 160,000
-------------- -------------- --------------
Total current liabilities.................................... 1,478,992 2,530,654 2,690,654
Obligations under capital leases, excluding current installments
(note 4)........................................................ 440,098 53,761 53,761
Long-term debt, excluding current installments (note 5).......... -- 693,528 693,528
-------------- -------------- --------------
Total liabilities............................................ 1,919,090 3,277,943 3,437,943
-------------- -------------- --------------
Commitments and contingencies (notes 3, 4, 9 and 12).............
Stockholders' equity (note 6):...................................
Preferred stock, $.001 par value; 5,000,000 shares authorized;
no shares issued and outstanding.............................. -- -- --
Common Stock, $.001 par value; 20,000,000 shares authorized;
issued and outstanding 6,787,358 shares at December 31, 1994,
7,072,801 shares at December 31, 1995, and 8,072,801 shares
pro forma..................................................... 6,787 7,073 8,073
Additional paid-in capital..................................... 27,847,067 28,067,130 35,566,130
Deferred compensation.......................................... (489,958) (234,458) (234,458)
Deficit accumulated during development stage................... (17,199,174) (20,517,265) (10,677,265)
-------------- -------------- --------------
Net stockholders' equity..................................... 10,164,722 7,322,480 24,662,480
-------------- -------------- --------------
$ 12,083,812 $ 10,600,423 $ 28,100,423
-------------- -------------- --------------
-------------- -------------- --------------
</TABLE>
See accompanying notes to financial statements.
F-3
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
OCTOBER 22,
1986
(INCEPTION)
YEAR ENDED DECEMBER 31, THROUGH
---------------------------------------------- DECEMBER 31,
1993 1994 1995 1995
-------------- -------------- -------------- ---------------
<S> <C> <C> <C> <C>
Revenues from research and license agreements... $ 867,568 $ 3,860,706 $ 9,562,319 $ 22,315,849
Operating expenses:
Research and development...................... 6,021,126 7,765,326 8,727,316 30,360,190
General and administrative.................... 2,003,699 3,121,688 3,975,379 12,788,445
-------------- -------------- -------------- ---------------
Total operating expenses.................... 8,024,825 10,887,014 12,702,695 43,148,635
-------------- -------------- -------------- ---------------
Operating loss.............................. (7,157,257) (7,026,308) (3,140,376) (20,832,786)
Other income (expense):
Interest income............................... 110,314 398,388 480,029 1,256,844
Interest expense.............................. (111,638) (128,413) (157,744) (475,713)
Other......................................... -- -- -- 34,390
-------------- -------------- -------------- ---------------
Total other income (expense)................ (1,324) 269,975 322,285 815,521
-------------- -------------- -------------- ---------------
Loss before income tax expense.............. (7,158,581) (6,756,333) (2,818,091) (20,017,265)
Income tax expense (note 7)..................... -- -- 500,000 500,000
-------------- -------------- -------------- ---------------
Net loss........................................ $ (7,158,581) $ (6,756,333) $ (3,318,091) $ (20,517,265)
-------------- -------------- -------------- ---------------
-------------- -------------- -------------- ---------------
Net loss per common share (note 1).............. $ (1.91) $ (1.13) $ (.48)
-------------- -------------- --------------
-------------- -------------- --------------
Weighted average shares outstanding (note 1).... 3,751,000 5,977,300 6,924,400
</TABLE>
See accompanying notes to financial statements.
F-4
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF STOCKHOLDERS' EQUITY
OCTOBER 22, 1986 (INCEPTION) THROUGH DECEMBER 31, 1995
<TABLE>
<CAPTION>
SERIES A SERIES B SERIES C SERIES D SERIES E
PREFERRED PREFERRED PREFERRED PREFERRED PREFERRED
STOCK STOCK STOCK STOCK STOCK
----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Issuance of 1,125,000 shares of common stock for cash and
equipment valued at fair value upon incorporation at
October 22, 1986.......................................... $ -- $ -- $ -- $ -- $ --
Net loss................................................... -- -- -- -- --
----------- ----------- ----- ----- -----
Balances, December 31, 1986................................ -- -- -- -- --
Repurchase of 375,000 shares of common stock............... -- -- -- -- --
Issuance of 82,500 shares of common stock for services..... -- -- -- -- --
Net income................................................. -- -- -- -- --
----------- ----------- ----- ----- -----
Balances, December 31, 1987................................ -- -- -- -- --
Issuance of 55,556 shares of preferred stock for cash...... 5,556 -- -- -- --
Issuance of 11,448 shares of common stock for cash upon
exercise of stock options................................. -- -- -- -- --
Issuance of 97,500 shares of common stock for services..... -- -- -- -- --
Net loss................................................... -- -- -- -- --
----------- ----------- ----- ----- -----
Balances, December 31, 1988................................ 5,556 -- -- -- --
Issuance of 37,037 shares of preferred stock for cash...... -- 3,704 -- -- --
Issuance of 7,500 shares of common stock for services...... -- -- -- -- --
Net loss................................................... -- -- -- -- --
----------- ----------- ----- ----- -----
Balances, December 31, 1989................................ 5,556 3,704 -- -- --
Issuance of 37,037 shares of preferred stock for cash...... -- 3,703 -- -- --
Issuance of 2,475 shares of common stock for cash upon
exercise of stock options................................. -- -- -- -- --
Net loss................................................... -- -- -- -- --
----------- ----------- ----- ----- -----
Balances, December 31, 1990................................ 5,556 7,407 -- -- --
<CAPTION>
DEFICIT
ACCUMULATED
ADDITIONAL DEFERRED DURING NET
COMMON PAID-IN COMPEN- DEVELOPMENT STOCKHOLDERS'
STOCK CAPITAL SATION STAGE EQUITY
----------- ---------- --------- ------------ ------------
<S> <C> <C> <C> <C> <C>
Issuance of 1,125,000 shares of common stock for cash and
equipment valued at fair value upon incorporation at
October 22, 1986.......................................... $ 1,125 $ 13,875 $ -- $ -- $ 15,000
Net loss................................................... -- -- -- (12,477) (12,477)
----------- ---------- --------- ------------ ------------
Balances, December 31, 1986................................ 1,125 13,875 -- (12,477) 2,523
Repurchase of 375,000 shares of common stock............... (375) (4,625) -- -- (5,000)
Issuance of 82,500 shares of common stock for services..... 83 1,017 -- -- 1,100
Net income................................................. -- -- -- 121,274 121,274
----------- ---------- --------- ------------ ------------
Balances, December 31, 1987................................ 833 10,267 -- 108,797 119,897
Issuance of 55,556 shares of preferred stock for cash...... -- 294,446 -- -- 300,002
Issuance of 11,448 shares of common stock for cash upon
exercise of stock options................................. 11 1,516 -- -- 1,527
Issuance of 97,500 shares of common stock for services..... 98 32,402 -- -- 32,500
Net loss................................................... -- -- -- (105,643) (105,643)
----------- ---------- --------- ------------ ------------
Balances, December 31, 1988................................ 942 338,631 -- 3,154 348,283
Issuance of 37,037 shares of preferred stock for cash...... -- 336,296 -- -- 340,000
Issuance of 7,500 shares of common stock for services...... 7 2,493 -- -- 2,500
Net loss................................................... -- -- -- (5,025) (5,025)
----------- ---------- --------- ------------ ------------
Balances, December 31, 1989................................ 949 677,420 -- (1,871) 685,758
Issuance of 37,037 shares of preferred stock for cash...... -- 336,297 -- -- 340,000
Issuance of 2,475 shares of common stock for cash upon
exercise of stock options................................. 2 898 -- -- 900
Net loss................................................... -- -- -- (212,976) (212,976)
----------- ---------- --------- ------------ ------------
Balances, December 31, 1990................................ 951 1,014,615 -- (214,847) 813,682
</TABLE>
F-5
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF STOCKHOLDERS' EQUITY (CONTINUED)
OCTOBER 22, 1986 (INCEPTION) THROUGH DECEMBER 31, 1995
<TABLE>
<CAPTION>
SERIES A SERIES B SERIES C SERIES D SERIES E
PREFERRED PREFERRED PREFERRED PREFERRED PREFERRED
STOCK STOCK STOCK STOCK STOCK
----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Issuance of 4,500 shares of common stock for cash upon
exercise of stock options................................ $ -- $ -- $ -- $ -- $ --
Net loss.................................................. -- -- -- -- --
----------- ----------- ----------- ----------- -----------
Balances, December 31, 1991............................... 5,556 7,407 -- -- --
Issuance of 3,675 shares of common stock for cash upon
exercise of stock options................................ -- -- -- -- --
Issuance of 230,334 shares of common stock upon conversion
of 129,630 shares of preferred stock..................... (5,556) (7,407) -- -- --
Repurchase and cancellation of 83,334 shares of common
stock for cash........................................... -- -- -- -- --
Issuance of 781,250 shares of preferred stock for cash,
net of offering costs.................................... -- -- 781 -- --
Issuance of 678,573 shares of preferred stock for cash,
net of offering costs.................................... -- -- -- 679 --
Issuance of 101,452 shares of common stock for services
related to preferred stock offering...................... -- -- -- -- --
Net loss.................................................. -- -- -- -- --
----------- ----------- ----------- ----------- -----------
Balances, December 31, 1992............................... -- -- 781 679
Issuance of 37,524 shares of common stock for cash upon
exercise of stock options................................ -- -- -- -- --
Issuance of 583,334 shares of preferred stock for cash,
net of offering costs.................................... -- -- -- -- 583
Issuance of 6,050 shares of preferred stock for
services................................................. -- -- -- -- 6
Deferred compensation related to grant of stock options... -- -- -- -- --
Net loss.................................................. -- -- -- -- --
----------- ----------- ----------- ----------- -----------
Balances, December 31, 1993............................... -- -- 781 679 589
<CAPTION>
DEFICIT
ACCUMULATED
ADDITIONAL DEFERRED DURING NET
COMMON PAID-IN COMPEN- DEVELOPMENT STOCKHOLDERS'
STOCK CAPITAL SATION STAGE EQUITY
----------- ----------- --------- ------------ ------------
<S> <C> <C> <C> <C> <C>
Issuance of 4,500 shares of common stock for cash upon
exercise of stock options................................ $ 5 $ 2,245 $ -- $ -- $ 2,250
Net loss.................................................. -- -- -- (462,054) (462,054)
----------- ----------- --------- ------------ ------------
Balances, December 31, 1991............................... 956 1,016,860 -- (676,901) 353,878
Issuance of 3,675 shares of common stock for cash upon
exercise of stock options................................ 4 2,221 -- -- 2,225
Issuance of 230,334 shares of common stock upon conversion
of 129,630 shares of preferred stock..................... 230 12,733 -- -- --
Repurchase and cancellation of 83,334 shares of common
stock for cash........................................... (83) (299,917) -- -- (300,000)
Issuance of 781,250 shares of preferred stock for cash,
net of offering costs.................................... -- 4,937,462 -- -- 4,938,243
Issuance of 678,573 shares of preferred stock for cash,
net of offering costs.................................... -- 4,693,794 -- -- 4,694,473
Issuance of 101,452 shares of common stock for services
related to preferred stock offering...................... 101 (101) -- -- --
Net loss.................................................. -- -- -- (2,607,359) (2,607,359)
----------- ----------- --------- ------------ ------------
Balances, December 31, 1992............................... 1,208 10,363,052 -- (3,284,260) 7,081,460
Issuance of 37,524 shares of common stock for cash upon
exercise of stock options................................ 38 25,545 -- -- 25,583
Issuance of 583,334 shares of preferred stock for cash,
net of offering costs.................................... -- 6,968,115 -- -- 6,968,698
Issuance of 6,050 shares of preferred stock for
services................................................. -- 72,594 -- -- 72,600
Deferred compensation related to grant of stock options... -- 766,500 (745,458) -- 21,042
Net loss.................................................. -- -- -- (7,158,581) (7,158,581)
----------- ----------- --------- ------------ ------------
Balances, December 31, 1993............................... 1,246 18,195,806 (745,458) (10,442,841) 7,010,802
</TABLE>
F-6
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF STOCKHOLDERS' EQUITY (CONTINUED)
OCTOBER 22, 1986 (INCEPTION) THROUGH DECEMBER 31, 1995
<TABLE>
<CAPTION>
SERIES A SERIES B SERIES C SERIES D SERIES E
PREFERRED PREFERRED PREFERRED PREFERRED PREFERRED
STOCK STOCK STOCK STOCK STOCK
----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Issuance of 3,475,666 shares of common stock upon
conversion of 2,049,207 shares of preferred stock........ $ -- $ -- $ (781) $ (679) $ (589)
Issuance of 2,000,000 shares of common stock for cash, net
of offering costs........................................ -- -- -- -- --
Issuance of 20,000 shares of common stock for services.... -- -- -- -- --
Issuance of 46,118 shares of common stock for cash upon
exercise of options...................................... -- -- -- -- --
Amortization of deferred compensation..................... -- -- -- -- --
Net loss.................................................. -- -- -- -- --
----------- ----------- ----------- ----------- -----------
Balances, December 31, 1994............................... -- -- -- -- --
Issuance of 242,385 shares of common stock for cash upon
exercise of options...................................... -- -- -- -- --
Issuance of 39,771 shares of common stock for cash........ -- -- -- -- --
Issuance of 3,287 shares of common stock for services..... -- -- -- -- --
Amortization of deferred compensation..................... -- -- -- -- --
Net loss.................................................. -- -- -- -- --
----------- ----------- ----------- ----------- -----------
Balances, December 31, 1995............................... $ -- $ -- $ -- $ -- $ --
----------- ----------- ----------- ----------- -----------
----------- ----------- ----------- ----------- -----------
See accompanying notes to financial statements.
<CAPTION>
DEFICIT
ACCUMULATED
ADDITIONAL DEFERRED DURING NET
COMMON PAID-IN COMPEN- DEVELOPMENT STOCKHOLDERS'
STOCK CAPITAL SATION STAGE EQUITY
----------- ----------- --------- ------------ ------------
<S> <C> <C> <C> <C> <C>
Issuance of 3,475,666 shares of common stock upon
conversion of 2,049,207 shares of preferred stock........ $ 3,475 $ (1,426) $ -- $ -- $ --
Issuance of 2,000,000 shares of common stock for cash, net
of offering costs........................................ 2,000 9,530,252 -- -- 9,532,252
Issuance of 20,000 shares of common stock for services.... 20 95,958 -- -- 95,978
Issuance of 46,118 shares of common stock for cash upon
exercise of options...................................... 46 26,477 -- -- 26,523
Amortization of deferred compensation..................... -- -- 255,500 -- 255,500
Net loss.................................................. -- -- -- (6,756,333) (6,756,333)
----------- ----------- --------- ------------ ------------
Balances, December 31, 1994............................... 6,787 27,847,067 (489,958) (17,199,174) 10,164,722
Issuance of 242,385 shares of common stock for cash upon
exercise of options...................................... 243 100,378 -- -- 100,621
Issuance of 39,771 shares of common stock for cash........ 40 109,827 -- -- 109,867
Issuance of 3,287 shares of common stock for services..... 3 9,858 -- -- 9,861
Amortization of deferred compensation..................... -- -- 255,500 -- 255,500
Net loss.................................................. -- -- -- (3,318,091) (3,318,091)
----------- ----------- --------- ------------ ------------
Balances, December 31, 1995............................... $ 7,073 $28,067,130 $(234,458) $(20,517,265) $7,322,480
----------- ----------- --------- ------------ ------------
----------- ----------- --------- ------------ ------------
See accompanying notes to financial statements.
</TABLE>
F-7
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
OCTOBER 22,
1986
(INCEPTION)
YEAR ENDED DECEMBER 31, THROUGH
---------------------------------------------- DECEMBER 31,
1993 1994 1995 1995
-------------- -------------- -------------- ---------------
<S> <C> <C> <C> <C>
Cash flows from operating activities:
Net loss...................................... $ (7,158,581) $ (6,756,333) $ (3,318,091) $ (20,517,265)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization............... 366,933 596,842 674,039 2,413,028
Gain on sale of equipment................... -- -- -- (28,720)
Issuance of common and preferred stock in
lieu of cash for services.................. 72,600 95,978 9,861 214,539
Amortization of deferred compensation....... 21,042 255,500 255,500 532,042
Decrease (increase) in operating assets:
Accounts receivable....................... 97,747 (226,788) 237,000 (23,000)
Other assets.............................. 28,819 (21,553) 24,874 (45,754)
Increase (decrease) in operating
liabilities:
Accounts payable and accrued expenses..... 435,818 142,592 110,187 1,176,178
Deferred income........................... 3,400,000 (3,400,000) 587,500 587,500
-------------- -------------- -------------- ---------------
Net cash used in operating activities... (2,735,622) (9,313,762) (1,419,130) (15,691,452)
Cash flows from investing activities:
Net sale (purchase) of marketable investment
securities................................... 1,589,384 (3,392,135) 3,092,135 (300,000)
Acquisition of equipment and leasehold
improvements................................. (1,206,683) (1,048,020) (373,171) (4,059,126)
Proceeds from sale of equipment............... 648,274 -- -- 1,048,484
-------------- -------------- -------------- ---------------
Net cash provided by (used in) investing
activities............................. 1,030,975 (4,440,155) 2,718,964 (3,310,642)
</TABLE>
F-8
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS (CONTINUED)
<TABLE>
<CAPTION>
OCTOBER 22,
1986
(INCEPTION)
YEAR ENDED DECEMBER 31, THROUGH
--------------------------------------------- DECEMBER 31,
1993 1994 1995 1995
-------------- -------------- ------------- ---------------
<S> <C> <C> <C> <C>
Cash flows from financing activities:
Proceeds from note payable to bank............. $ -- $ -- $ -- $ 123,855
Proceeds from issuance of preferred stock and
collection of subscription receivable......... 2,968,698 4,000,000 -- 17,581,416
Proceeds from issuance of common stock......... 25,583 9,558,775 210,488 9,811,748
Proceeds from long-term debt................... -- -- 1,166,434 1,166,434
Principal payments on note payable to bank..... -- -- -- (123,855)
Principal payments under capital lease
obligations................................... (53,618) (287,539) (427,053) (879,415)
Principal payments on long-term debt........... (11,489) -- (141,160) (338,464)
Repurchase of preferred stock.................. -- -- -- (300,000)
-------------- -------------- ------------- ---------------
Net cash provided by financing activities.... 2,929,174 13,271,236 808,709 27,041,719
-------------- -------------- ------------- ---------------
Net increase (decrease) in cash and cash
equivalents..................................... 1,224,527 (482,681) 2,108,543 8,039,625
Cash and cash equivalents at beginning of
period.......................................... 5,189,236 6,413,763 5,931,082 --
-------------- -------------- ------------- ---------------
Cash and cash equivalents at end of period....... $ 6,413,763 $ 5,931,082 $ 8,039,625 $ 8,039,625
-------------- -------------- ------------- ---------------
-------------- -------------- ------------- ---------------
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest........................... $ 91,038 $ 149,013 $ 171,752 $ 475,713
Cash paid for taxes.............................. -- -- 500,000 500,000
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND
FINANCING ACTIVITIES
Acquisition of equipment through incurrence of
capital lease obligations....................... $ 648,274 $ 25,669 $ 62,945 $ 1,368,406
Acquisition of leasehold improvements through
incurrence of debt.............................. -- -- -- 197,304
Issuance of preferred stock for stock
subscription receivable......................... 4,000,000 -- -- 4,000,000
Accrual of deferred offering costs............... 150,000 -- -- 150,000
</TABLE>
See accompanying notes to financial statements.
F-9
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1993, 1994, AND 1995
(1) ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NPS Pharmaceuticals, Inc. (the "Company"), considered a development stage
company under the guidelines of STATEMENT OF FINANCIAL ACCOUNTING STANDARDS NO.
7, is engaged in the discovery and commercial development of novel
pharmaceutical products, primarily small molecule drugs that target cell surface
receptors and ion channels. Since inception, the Company's principal activities
have been performing research and development, raising capital, and establishing
research and license agreements. The following significant accounting policies
are followed by the Company in preparing its financial statements:
(a) CASH EQUIVALENTS
Cash equivalents of $4.8 million and $5.4 million at December 31, 1994
and 1995, respectively, consist of short-term securities and certificates of
deposit with an initial term of less than three months. For purposes of the
statements of cash flows, the Company considers all highly liquid debt
instruments with original maturities of three months or less to be cash
equivalents.
(b) REVENUE RECOGNITION
The Company recognizes revenue from its research agreements as related
research costs are incurred and from its license fees and milestone payments
as earned. Cash received in advance of the performance of the related
research is recorded as deferred income.
(c) PLANT AND EQUIPMENT
Plant and equipment are stated at cost. Equipment under capital lease is
stated at the lower of the present value of minimum lease payments at the
beginning of the lease term or fair value of the equipment at the inception
of the lease.
Depreciation and amortization of equipment (including equipment held
under capital lease) is calculated on the straight-line method over their
estimated useful lives of five years. Leasehold improvements are amortized
using the straight-line method over the shorter of the life of the asset or
remainder of the lease term. Amortization of assets held under capital
leases is included with depreciation and amortization expense.
(d) NET LOSS PER SHARE
The Company's loss per share is based on the weighted average number of
common shares outstanding during the periods. Common stock equivalents
(stock options and warrants) have been excluded in the computation as their
inclusion would have an antidilutive effect. For periods prior to May 26,
1994, the date of the Company's initial public offering, upon which all
outstanding shares of preferred stock were converted to shares of common
stock, the loss presented is pro forma after giving retroactive effect to
the conversion of Series C, D, and E preferred stock and the inclusion of
common stock options issued for consideration below the initial public
offering price during the twelve-month period prior to the date of the
initial filing of the Registration Statement, even when antidilutive,
pursuant to Securities and Exchange Commission Staff Accounting Bulletin No.
83, using the treasury-stock method.
F-10
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(1) ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
(e) INCOME TAXES
The Company accounts for income taxes using the asset and liability
method. Under the asset and liability method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases, operating loss, and
tax credit carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates
is recognized in income in the period that includes the enactment date.
(f) USE OF ESTIMATES
Management of the Company has made estimates and assumptions relating to
reporting of assets and liabilities and the disclosure of contingent assets
and liabilities to prepare these financial statements in conformity with
generally accepted accounting principles. Actual results could differ from
those estimates.
(g) MARKETABLE INVESTMENT SECURITIES
The Company adopted the provisions of Statement of Financial Accounting
Standards No. 115, ACCOUNTING FOR CERTAIN INVESTMENTS IN DEBT AND EQUITY
("Statement 115"), January 1, 1994. Statement 115 requires that debt and
equity securities be grouped in one of three categories: trading,
available-for-sale, or held-to-maturity. Trading securities are bought and
held principally for the purpose of selling them in the near term.
Held-to-maturity securities are those securities in which the Company has
the ability and intent to hold the security until maturity. All other
securities not included in trading or held-to-maturity are classified as
available-for-sale. The effect of this adoption of Statement 115 was not
material to the Company's financial statements.
Available-for sale securities are recorded at fair value.
Held-to-maturity securities are recorded at amortized cost, adjusted for the
amortization or accretion of premiums or discounts. Unrealized holding gains
and losses, net of the related tax effect, on available-for-sale securities
are excluded from earnings and are reported as a separate component of
stockholders' equity until realized. Realized gains and losses from the sale
of available-for-sale securities are determined on a specific-identification
basis.
A decline in the market value of any available-for-sale or
held-to-maturity security below cost that is deemed other than temporary
results in a reduction in carrying amount to fair value. The impairment is
charged to earnings and a new cost basis for the security is established.
Premiums and discounts are amortized or accreted over the life of the
related held-to-maturity security as an adjustment to yield using the
effective interest method. Dividend and interest income are recognized when
earned.
F-11
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(2) MARKETABLE INVESTMENT SECURITIES
The amortized cost, gross unrealized holding gains, gross unrealized holding
losses and fair value for available-for-sale and held-to-maturity securities by
major security type and class of security at December 31, 1994 and 1995, were as
follows:
<TABLE>
<CAPTION>
GROSS
GROSS UNREALIZED
AMORTIZED UNREALIZED HOLDING
COST HOLDING GAINS LOSSES FAIR VALUE
------------- --------------- ----------- -------------
<S> <C> <C> <C> <C>
At December 31, 1994
Held-to-maturity:
Corporate obligations (due within one year)............... $ 3,392,135 -- $ 296 $ 3,391,839
At December 31, 1995
Available-for-sale:
Corporate obligations (due within one year)............... $ 300,000 -- -- $ 300,000
</TABLE>
(3) COLLABORATIVE AND LICENSE AGREEMENTS
The Company is pursuing product development both on an independent basis and
in collaboration with others. Following is a description of significant current
collaborations and license agreements.
(a) KIRIN BREWERY COMPANY, LIMITED
Effective June 30, 1995, NPS entered into a five year agreement with the
pharmaceutical division of Kirin Brewery Company, Limited (a Japanese
company), to develop and commercialize Norcalcin in Japan, China, Korea, and
Taiwan. Kirin paid to NPS a $5.0 million license fee and has agreed to pay
up to $7.0 million in research support, potential additional milestone
payments totaling $13.0 million, and royalties on product sales. The Kirin
research support payments are $500,000 per quarter through June 1996 and a
total of $5.0 million over the remaining four years. Kirin received
exclusive rights to develop and sell Norcalcin within its territory. Both
parties will participate in a collaborative research program around NPS's
parathyroid calcium receptor technology.
The Company recognized the $5.0 million nonrefundable license fee and
$1.0 million in research support as revenue in 1995. The agreement may be
terminated by Kirin after June 30, 1996.
(b) SMITHKLINE BEECHAM CORPORATION
Effective November 1, 1993, the Company entered into the SmithKline
Beecham Agreement ("SB Agreement") to collaborate on the discovery,
development and marketing of drugs to treat osteoporosis and other bone
metabolism disorders, excluding hyperparathyroidism. The SB Agreement
establishes a three year research collaboration between the parties, which
may be extended on mutual agreement. Under the SB Agreement, the Company
granted SmithKline Beecham the exclusive license to develop and market
worldwide compounds described under the SB Agreement, subject to the
Company's right to co-promote in the United States. Once compounds have been
selected for development, SmithKline Beecham has agreed to conduct and fund
all development of such products, including all human clinical trials and
regulatory submissions.
The Company received an initial licensing fee payment of $4.0 million in
November 1993 and received an additional $2.0 million payment in January
1995. The Company recognized this
F-12
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(3) COLLABORATIVE AND LICENSE AGREEMENTS (CONTINUED)
(b) SMITHKLINE BEECHAM CORPORATION (CONTINUED)
revenue as the related research costs were incurred, and recognized $600,000
in 1993, $3.6 million in 1994 and $1.8 million in 1995. Commencing on July
1, 1995, the Company began receiving quarterly research payments from
SmithKline Beecham to support research efforts through the scheduled
expiration of the research term on October 31, 1996, if not previously
terminated. The Company recognized $1.6 million from such payments in 1995.
The Company is also entitled to receive payments upon the achievement of
specific development and regulatory milestones. The Company will receive
royalties on sales of such compounds by SmithKline Beecham and a share of
the profits from co-promoted products.
S.R. One, Limited, an affiliate of SmithKline Beecham, is an equity
investor in the Company.
Subsequent to year-end, the Company reached its first milestone under
the SB Agreement and received a corresponding milestone payment of $3.0
million.
(c) THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
In February 1993, the Company entered into two agreements with The
Brigham and Women's Hospital, Inc. (the "Hospital"). Under the first
agreement, the Company received an exclusive license to the Hospital's
calcium receptor patentable technology at that date. The Company will pay
milestone payments to the Hospital and a royalty on sales of products
covered by any issued patent under the license. The Company also entered
into an agreement to sponsor research through February 28, 1996 at the
Hospital in the amount of $300,000 per year and the Hospital granted to the
Company a right of first negotiation for license rights to any newly
discovered patentable calcium receptor technology. During 1993, 1994, and
1995, the Company paid to the Hospital $400,241, $320,121, and $306,777,
respectively, in sponsored research payments and license fees.
On February 7, 1996, the Company reached an agreement with the Hospital
to extend the sponsored collaborative research agreement. Under the terms of
the extension, the Company has agreed to continue funding research for an
additional two years. The extended research agreement calls for the Company
to make research support and advance royalty payments of $810,000 to the
Hospital during the period from February 1996 to February 1998.
(d) SMALL BUSINESS INNOVATION RESEARCH GRANTS
The Company recognized revenue of $267,568, $260,706, and $126,444
during 1993, 1994, and 1995, respectively, under the terms of Small Business
Innovation Research grants from three government agencies.
F-13
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(4) LEASES
The Company is obligated under capital leases for equipment that expire at
various dates during the next three years. The Company also has a noncancelable
operating lease for office space that expires in September 1999. Rental expense
for this operating lease was $340,276, $413,552, and $493,667 for 1993, 1994,
and 1995, respectively. The present value of future minimum lease payments on
capital leases and future lease payments under the noncancelable operating lease
as of December 31, 1995 are:
<TABLE>
<CAPTION>
CAPITAL OPERATING
LEASES LEASE
----------- -------------
<S> <C> <C>
Year ending December 31:
1996............................................................ $ 466,129 $ 525,919
1997............................................................ 48,123 525,919
1998............................................................ 9,127 525,919
1999............................................................ -- 394,439
----------- -------------
Total minimum lease payments.................................. 523,379 $ 1,972,196
-------------
-------------
Less amounts representing interest (at rates ranging from 6% to
16%)............................................................. 34,388
-----------
Present value of net minimum capital lease payments............... 488,991
Less current installments of obligations under capital leases..... 435,230
-----------
Obligations under capital leases, excluding current
installments................................................. $ 53,761
-----------
-----------
</TABLE>
At December 31, 1994 and 1995, the gross amount of equipment and related
accumulated amortization recorded under capital leases was as follows:
<TABLE>
<CAPTION>
1994 1995
------------- -------------
<S> <C> <C>
Equipment....................................................... $ 1,232,980 $ 1,212,699
Less accumulated amortization................................... 572,090 748,881
------------- -------------
Net equipment............................................... $ 660,890 $ 463,818
------------- -------------
------------- -------------
</TABLE>
The Company has granted a leasing company a warrant to purchase 20,250
common shares at $4.67 per share. The warrant expires in May 1996.
(5) LONG-TERM DEBT
Long-term debt at December 31, 1995 consists of the following notes payable
to a financial institution:
<TABLE>
<S> <C>
10% to 16% notes payable in monthly installments of $37,105
including interest, due June 1, 1998 through June 1, 1999;
secured by certain equipment and leasehold improvements....... $1,025,274
Less, current installments..................................... 331,746
----------
Long-term debt, excluding current installments............. $ 693,528
----------
----------
</TABLE>
The aggregate maturities of long-term debt for each of the years
subsequent to December 31, 1995 are as follows: 1996, $331,746; 1997,
$378,613; 1998, $302,065; and 1999, $12,850.
F-14
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(5) LONG-TERM DEBT (CONTINUED)
In connection with these notes payable, the Company granted the
financial institution a warrant to purchase 32,542 shares of common stock at
$3.69 per share. The warrant expires in June 2002.
(6) CAPITAL STOCK
The Company is incorporated under the laws of the State of Delaware with
authorized capital of 5,000,000 shares of preferred stock and 20,000,000 shares
of common stock, all with a par value of $.001. No shares of preferred stock
were issued or outstanding at December 31, 1994 and 1995.
The Company has three stock option plans: the 1987 Stock Option Plan (the
"1987 Plan"), the 1994 Equity Incentive Plan (the "1994 Plan"), and the 1994
Non-Employee Directors' Stock Option Plan (the "Directors' Plan"). An aggregate
of 2,390,000 shares are authorized for issuance under the three plans. As of
December 31, 1995, there are no shares reserved for future grant under the 1987
Plan, there are 315,503 shares reserved for future grant under the 1994 Plan,
and there are 36,000 shares reserved for future grant under the Directors' Plan.
Under the Company's 1994 Plan, the exercise price of options granted is not less
than the fair market value on the date of grant. The number of shares, terms,
and exercise period are determined by the Board of Directors on an option-
by-option basis, but the exercise period does not extend beyond ten years from
the date of the grant.
Under the Directors' Plan, each new director who is not an employee of the
Company will be granted an option to purchase 15,000 shares of common stock.
Additional options will be granted at December 31 of each subsequent year. The
exercise price of options granted is the fair market value on the date of grant.
A summary of activity related to aggregate options under all three plans is
indicated in the following table:
<TABLE>
<CAPTION>
1993 1994 1995
--------------------------- ----------------------------- -----------------------------
OPTIONS EXERCISE PRICE OPTIONS EXERCISE PRICE OPTIONS EXERCISE PRICE
----------- -------------- ----------- ---------------- ----------- ----------------
<S> <C> <C> <C> <C> <C> <C>
Outstanding,
beginning of
year.............. 719,400 $ .34 - .81 1,192,875 $ .34 - 4.00 1,419,125 $ .34 - 6.00
Granted............ 511,500 .74 - 4.00 309,800 3.00 - 6.00 374,000 3.50 - 8.25
Exercised.......... (37,524) .34 - .74 (46,118) .34 - .74 (257,633) .34 - 2.00
Canceled........... (501) - .74 (37,432) .34 - 4.00 (4,568) 2.00 - 3.00
----------- -------------- ----------- ---------------- ----------- ----------------
Outstanding, end of
year.............. 1,192,875 $ .34 - 4.00 1,419,125 $ .34 - 6.00 1,530,924 $ .34 - 8.25
----------- -------------- ----------- ---------------- ----------- ----------------
----------- -------------- ----------- ---------------- ----------- ----------------
</TABLE>
Exercise of options by employees, consultants, and directors has been made
subject to vesting based on job tenure and as of December 31, 1995, options to
purchase 802,540 shares of common stock are vested and exercisable.
In November and December 1993, the Company issued options to purchase
378,750 and 4,500 shares of common stock, respectively, at an exercise price of
$2.00 and $4.00 per share, respectively, to employees, officers, and directors
of the Company. For financial statement presentation purposes, the Company has
recorded as deferred compensation expense the excess of the deemed value of the
F-15
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(6) CAPITAL STOCK (CONTINUED)
common stock at the date of grant over the exercise price. The compensation
expense will be amortized ratably over the three-year vesting period of the
options and will aggregate $766,500 over such period. During 1995, employees
exercised 257,633 stock options utilizing 15,248 common shares and cash for
242,385 common shares.
The Company's 1994 Employee Stock Purchase Plan (the "Purchase Plan") has
90,000 shares authorized for purchase by employees of the Company. Employees
have purchased 39,771 shares under the Purchase Plan as of December 31, 1995,
and 50,229 shares remain available for future purchase.
(7) INCOME TAXES
The Company has income tax expense of $500,000 for the year ended December
31, 1995 consisting of current foreign taxes.
Income tax expense differed from the amounts computed by applying the U.S.
federal income tax rate of 34 percent to net income (loss) before income taxes
as a result of the following:
<TABLE>
<CAPTION>
1993 1994 1995
-------------- -------------- --------------
<S> <C> <C> <C>
Computed expected tax benefit........................... $ (2,433,918) $ (2,297,153) $ (958,150)
Change in the beginning-of-the-year balance of the
valuation allowance for deferred tax assets allocated
to income tax expense.................................. 2,621,555 2,376,354 1,279,785
Foreign taxes net of federal income tax benefit......... -- -- 330,000
Other................................................... (187,637) (79,201) (151,635)
-------------- -------------- --------------
$ -- $ -- $ 500,000
-------------- -------------- --------------
-------------- -------------- --------------
</TABLE>
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets at December 31, 1994 and 1995 are presented
below:
<TABLE>
<CAPTION>
1994 1995
-------------- --------------
<S> <C> <C>
Deferred tax assets:
Deferred revenue............................................ $ -- $ 220,000
Equipment and leasehold improvements, principally due to
differences in depreciation................................ 183,000 159,000
Net operating loss carryforward............................. 5,815,000 6,873,000
Research activities credit carryforward..................... 803,000 953,000
-------------- --------------
Total gross deferred tax assets........................... 6,801,000 8,205,000
Less valuation allowance.................................. 6,801,000 8,205,000
-------------- --------------
Net deferred tax assets................................... $ -- $ --
-------------- --------------
-------------- --------------
</TABLE>
Subsequently recognized tax benefits relating to the valuation allowance for
deferred tax assets as of December 31, 1995 will be allocated as an income tax
benefit to be reported in the statement of operations.
The valuation allowance for deferred tax assets as of January 1, 1994 was
$4.2 million. The net change in the Company's total valuation allowance for the
years ended December 31, 1994 and 1995 was an increase of $2.6 million and $1.4
million, respectively.
F-16
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(7) INCOME TAXES (CONTINUED)
At December 31, 1995, the Company had net operating loss and research credit
carryforwards to offset future income for federal income tax purposes
approximately as follows:
<TABLE>
<CAPTION>
NET OPERATING
LOSS CARRYFORWARD NET OPERATING LOSS
FOR REGULAR CARRYFORWARD FOR RESEARCH
INCOME TAX ALTERNATIVE MINIMUM CREDIT
PURPOSES TAX PURPOSES CARRYFORWARD
----------------- ------------------- ------------
<S> <C> <C> <C>
Expiring
2002........................................... $ -- $ -- $ 2,000
2003........................................... -- -- 14,000
2004........................................... 159,000 90,000 18,000
2005........................................... 292,000 273,000 20,000
2006........................................... 1,377,000 1,385,000 48,000
2007........................................... 1,141,000 1,321,000 49,000
2008........................................... 3,132,000 3,425,000 335,000
2009........................................... 9,493,000 9,492,000 317,000
2010........................................... 2,832,000 2,939,000 150,000
----------------- ------------------- ------------
$ 18,426,000 $ 18,925,000 $ 953,000
----------------- ------------------- ------------
----------------- ------------------- ------------
</TABLE>
Under the rules of the Tax Reform Act of 1986, the Company has undergone a
greater than 50 percent change of ownership since 1986. Consequently, use of the
Company's net operating loss carryforward and research credit carryforward
against future taxable income in any one year may be limited. The maximum amount
of carryforwards available in a given year is limited to the product of the
Company's fair market value on the date of ownership change and the federal
long-term tax-exempt rate, plus any limited carryforward not utilized in prior
years.
(8) EMPLOYEE BENEFIT PLAN
In October 1990, the Company adopted a tax-qualified employee savings and
retirement plan (the "401(k) Plan") covering all of the Company's employees.
Pursuant to the 401(k) Plan, employees may elect to reduce their current
compensation by the lesser of 15 percent of eligible compensation or the
prescribed annual limit ($9,240 in 1995) and have the amount of such reduction
contributed to the 401(k) Plan. The 401(k) Plan permits, but does not require,
additional matching contributions to the 401(k) Plan by the Company on behalf of
all participants. The Company has not made any such contributions to date.
(9) CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
A director of the Company is Vice President of Plexus Ventures, Inc.
("Plexus"). The Company had a consulting agreement with Plexus through December
31, 1995, whereunder Plexus assisted the Company with its effort to estalish a
collaboration for Norcalcin in Europe. During the years ended December 31, 1994,
and 1995, the Company paid fees to Plexus totaling $34,000 and $84,500,
respectively. Plexus will earn an additional fee as payments are received from
Amgen. Under the agreement the maximum additional fee is $500,000, but the
Company and Plexus have agreed to negotiate in good faith for an increase in the
maximum because of the non-European territory licensed to Amgen.
(10)ACCOUNTING STANDARDS NOT YET ADOPTED
In October of 1995, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 123, ACCOUNTING FOR STOCK BASED
COMPENSATION ("FASB 123"). The
F-17
<PAGE>
NPS PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1993, 1994, AND 1995
(10)ACCOUNTING STANDARDS ISSUED NOT YET ADOPTED (CONTINUED)
Company is required to adopt the provisions of this statement for years
beginning after December 15, 1995. This statement encourages all entities to
adopt a fair value based method of accounting for employee stock options or
similar equity instruments. However, it also allows an entity to continue to
measure compensation cost for those plans using the intrinsic-value method of
accounting prescribed by APB opinion No. 25, ACCOUNTING FOR STOCK ISSUED TO
EMPLOYEES ("APB 25"). Entities electing to remain with the accounting in APB 25
must make pro forma disclosures of net income and earnings per share as if the
fair value based method of accounting defined in this statement had been
applied. It is currently anticipated that the Company will continue to measure
compensation costs in accordance with APB 25 and provide the disclosures
required by FASB 123.
(11)SUBSEQUENT EVENTS
On March 18, 1996, the Company entered into a development and license
agreement with Amgen Inc. ("Amgen") to develop and commercialize Norcalcin-TM-
and other compounds for the treatment of hyperparathyroidism and indications
other than osteoporosis. Amgen agreed to pay to the Company a $10.0 million
non-refundable license fee, potential additional development milestone payments
totaling $26.0 million, and royalties on any future product sales. Amgen also
agreed to purchase one million shares of the Company's common stock for $7.5
million. Amgen is required to pay all costs of developing and commercializing
products. Amgen received exclusive worldwide rights (excluding Japan, China,
Korea and Taiwan). The agreement may be terminated by Amgen at any time.
The Company received the $10.0 million license fee upon the signing of the
definitive agreement in March 1996. It is anticipated that closing of the stock
agreement and issuance of the shares will take place in March 1996. The pro
forma balance sheet at December 31, 1995 reflects receipt from Amgen of the
$10.0 million license fee and the issuance of the Common Stock for cash of $7.5
million.
(12)CONTINGENCY
The Company is subject to federal, state and local environmental laws and
regulations. It is the policy of the Company to comply with these laws and
regulations. The Company has received a letter from the United States
Environmental Protection Agency notifying the Company that it may have incurred
a liability for two barrels of radioactive waste taken by a third party
contractor to a hazardous and radioactivity waste storage treatment and disposal
facility. The Company has verified that the two barrels containing the waste
have been removed from the disposal facility and believes, based upon an
inspection, that the barrels neither leaked nor were damaged. The Company has
made no provision for any future liability for this contingency since any amount
of potential liability is not reasonably estimable.
F-18
